These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37175668)

  • 21. Noonan syndrome-like phenotype associated with an ERF frameshift variant.
    Hirano Y; Kuroda Y; Enomoto Y; Naruto T; Muroya K; Kurosawa K
    Am J Med Genet A; 2024 May; ():e63652. PubMed ID: 38741564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mice lacking the conserved transcription factor Grainyhead-like 3 (Grhl3) display increased apposition of the frontal and parietal bones during embryonic development.
    Goldie SJ; Arhatari BD; Anderson P; Auden A; Partridge DD; Jane SM; Dworkin S
    BMC Dev Biol; 2016 Oct; 16(1):37. PubMed ID: 27756203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. De novo mutations in inhibitors of Wnt, BMP, and Ras/ERK signaling pathways in non-syndromic midline craniosynostosis.
    Timberlake AT; Furey CG; Choi J; Nelson-Williams C; ; Loring E; Galm A; Kahle KT; Steinbacher DM; Larysz D; Persing JA; Lifton RP
    Proc Natl Acad Sci U S A; 2017 Aug; 114(35):E7341-E7347. PubMed ID: 28808027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential repression of c-myc and cdc2 gene expression by ERF and PE-1/METS.
    Hester KD; Verhelle D; Escoubet-Lozach L; Luna R; Rose DW; Glass CK
    Cell Cycle; 2007 Jul; 6(13):1594-604. PubMed ID: 17525531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Semaphorin-7a reverses the ERF-induced inhibition of EMT in Ras-dependent mouse mammary epithelial cells.
    Allegra M; Zaragkoulias A; Vorgia E; Ioannou M; Litos G; Beug H; Mavrothalassitis G
    Mol Biol Cell; 2012 Oct; 23(19):3873-81. PubMed ID: 22875994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis.
    Shukla V; Coumoul X; Wang RH; Kim HS; Deng CX
    Nat Genet; 2007 Sep; 39(9):1145-50. PubMed ID: 17694057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ERF: genomic organization, chromosomal localization and promoter analysis of the human and mouse genes.
    Liu D; Pavlopoulos E; Modi W; Moschonas N; Mavrothalassitis G
    Oncogene; 1997 Mar; 14(12):1445-51. PubMed ID: 9136988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Ets2 Repressor Factor (Erf) Is Required for Effective Primitive and Definitive Hematopoiesis.
    Peraki I; Palis J; Mavrothalassitis G
    Mol Cell Biol; 2017 Oct; 37(19):. PubMed ID: 28694332
    [No Abstract]   [Full Text] [Related]  

  • 29. Overexpression of
    Lee KKL; Peskett E; Quinn CM; Aiello R; Adeeva L; Moulding DA; Stanier P; Pauws E
    Dis Model Mech; 2018 Nov; 11(11):. PubMed ID: 30266836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ETS2 repressor factor (ERF) is involved in T lymphocyte maturation acting as regulator of thymocyte lineage commitment.
    Tsiomita S; Liveri EM; Vardaka P; Vogiatzi A; Skiadaresis A; Saridis G; Tsigkas I; Michaelidis TM; Mavrothalassitis G; Thyphronitis G
    J Leukoc Biol; 2022 Oct; 112(4):641-657. PubMed ID: 35258130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF.
    Chou YT; Lin HH; Lien YC; Wang YH; Hong CF; Kao YR; Lin SC; Chang YC; Lin SY; Chen SJ; Chen HC; Yeh SD; Wu CW
    Cancer Res; 2010 Nov; 70(21):8822-31. PubMed ID: 20978205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ets domain transcription factor PE1 suppresses human interstitial collagenase promoter activity by antagonizing protein-DNA interactions at a critical AP1 element.
    Bidder M; Loewy AP; Latifi T; Newberry EP; Ferguson G; Willis DM; Towler DA
    Biochemistry; 2000 Aug; 39(30):8917-28. PubMed ID: 10913304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevated expression of Ets2 or distinct portions of Ets2 can reverse Ras-mediated cellular transformation.
    Foos G; García-Ramírez JJ; Galang CK; Hauser CA
    J Biol Chem; 1998 Jul; 273(30):18871-80. PubMed ID: 9668063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proteins of the ETS family with transcriptional repressor activity.
    Mavrothalassitis G; Ghysdael J
    Oncogene; 2000 Dec; 19(55):6524-32. PubMed ID: 11175368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A craniosynostosis massively parallel sequencing panel study in 309 Australian and New Zealand patients: findings and recommendations.
    Lee E; Le T; Zhu Y; Elakis G; Turner A; Lo W; Venselaar H; Verrenkamp CA; Snow N; Mowat D; Kirk EP; Sachdev R; Smith J; Brown NJ; Wallis M; Barnett C; McKenzie F; Freckmann ML; Collins F; Chopra M; Gregersen N; Hayes I; Rajagopalan S; Tan TY; Stark Z; Savarirayan R; Yeung A; Adès L; Gattas M; Gibson K; Gabbett M; Amor DJ; Lattanzi W; Boyd S; Haan E; Gianoutsos M; Cox TC; Buckley MF; Roscioli T
    Genet Med; 2018 Sep; 20(9):1061-1068. PubMed ID: 29215649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ERF deletion rescues RAS deficiency in mouse embryonic stem cells.
    Mayor-Ruiz C; Olbrich T; Drosten M; Lecona E; Vega-Sendino M; Ortega S; Dominguez O; Barbacid M; Ruiz S; Fernandez-Capetillo O
    Genes Dev; 2018 Apr; 32(7-8):568-576. PubMed ID: 29650524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis.
    Bose R; Karthaus WR; Armenia J; Abida W; Iaquinta PJ; Zhang Z; Wongvipat J; Wasmuth EV; Shah N; Sullivan PS; Doran MG; Wang P; Patruno A; Zhao Y; ; Zheng D; Schultz N; Sawyers CL
    Nature; 2017 Jun; 546(7660):671-675. PubMed ID: 28614298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The transcriptional ETS2 repressor factor associates with active and inactive Erks through distinct FXF motifs.
    Polychronopoulos S; Verykokakis M; Yazicioglu MN; Sakarellos-Daitsiotis M; Cobb MH; Mavrothalassitis G
    J Biol Chem; 2006 Sep; 281(35):25601-11. PubMed ID: 16799155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic basis of potential therapeutic strategies for craniosynostosis.
    Melville H; Wang Y; Taub PJ; Jabs EW
    Am J Med Genet A; 2010 Dec; 152A(12):3007-15. PubMed ID: 21082653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic background dependent modifiers of craniosynostosis severity.
    Dudakovic A; Nam HK; Wijnen AJV; Hatch NE
    J Struct Biol; 2020 Dec; 212(3):107629. PubMed ID: 32976998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.